MULTABODY
LIVE

Serial Number

98081053

Owner

Radiant Biotherapeutics

Attorney

Tom M. Monagan

Filing Date

Jul 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MULTABODY Trademark

Serial Number: 98081053

MULTABODY is a trademark filed by Radiant Biotherapeutics on July 12, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

Radiant Biotherapeutics (2 trademarks)

PGCRL 21.9430.X, Admin Rm 21.9800 U1 E
Toronto, ON M5G0A4 , CA

Entity Type: 03

Trademark Details

Filing Date

July 12, 2023

Registration Date

Not Registered

Published for Opposition

April 8, 2025

Goods & Services

Medical, scientific and biological research; research in antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these and development services of new pharmaceutical products based on antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; development of pharmaceutical preparations and medicines containing antibodies, bi- and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; medical and scientific research, namely, biological scientific research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases

Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as fragments, monovalent antibodies, derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemicals, namely, monoclonal antibodies for in vivo or in vitro scientific research and development regarding cancer, AIDS (acquired immune deficiency syndrome), and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases

Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases; pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases

Licensing of intellectual property in the field of medicine

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 2, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 1, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 1, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 1, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 28, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 28, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 28, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 28, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 28, 2025 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 3, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 22, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 10, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 10, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 22, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 22, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 22, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 20, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2023 NWOS
NEW APPLICATION ENTERED
Jul 15, 2023 NWAP